Update on ACCENT Trial in Pancreatic Cancer
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
- Amplia Reports First Patient Dosing In Phase 2a Accent Trial
- Approval to Initiate Phase2 Pancreatic Cancer Trial in Korea
- Appendix 4D and Financial Report Half Year ended 30 Sep 23
- Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
Later from Amplia Therapeutics
- Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27
- Rights Issue Investor Slide Deck
- $4.27m Offer Successfully Completed and ACCENT Trial Update
- Preliminary Final Report and Annual Report YE 31 March 2024
- First 26 Patients recruited in Phase 2A ACCENT Trial
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics